The clinical impact of androgen deprivation therapy on SARS-CoV-2 infection rates and disease severity.

IF 1 Q4 UROLOGY & NEPHROLOGY
Özgür Kazan, Meftun Çulpan, Özgür Efiloğlu, Gökhan Atiş, Asıf Yildirim
{"title":"The clinical impact of androgen deprivation therapy on SARS-CoV-2 infection rates and disease severity.","authors":"Özgür Kazan,&nbsp;Meftun Çulpan,&nbsp;Özgür Efiloğlu,&nbsp;Gökhan Atiş,&nbsp;Asıf Yildirim","doi":"10.5152/tud.2021.21278","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The protective effect of androgen deprivation therapy (ADT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel hypothesis. ADT may protect patients with prostate cancer through the inhibition of androgen receptor-dependent transmembrane serine protease type 2. We analyzed the role of ADT on SARS-CoV-2 infection risk and disease severity.</p><p><strong>Material and methods: </strong>Between August 2020 and June 2021, patients with prostate cancer were included in our study. Patients were divided into two groups as men receiving ADT or not. Patients' characteristics such as prostate cancer grade and stage, comorbidities, SARS-CoV-2 infection status, and infection severity were assessed. SARS-CoV-2-infected close relatives and patients' compliance with the precautions against SARSCoV- 2 were also analyzed.</p><p><strong>Results: </strong>A total of 365 patients, 138 (37.8%) with ADT and 227 (62.2%) without ADT, were included in our analysis. Patients with ADT were older (71.8 vs 66.9 years, P ¼ .001) and had a higher rate of chronic obstructive pulmonary disease (11.6% vs 5.7%, P ¼ .044). Patients receiving ADT were more often locally advanced and metastatic (80.4% vs 32.6%, P ¼ .001). SARS-CoV-2 infection rates were statistically similar between patients who received and did not receive ADT (9.4% vs 13.2%, P ¼ .275, respectively). There was no significant difference between two groups in terms of hospitalization rates (2.9% vs 0.9%, P ¼ .205). In multivariate analysis, the presence of SARS-CoV-2-infected close relatives and precautions score were only independent predictors for both risk of SARS-CoV-2 infection and infection severity.</p><p><strong>Conclusion: </strong>We could not find any effect of ADT on risk and severity of SARS-CoV-2 infection. SARSCoV- 2 infection and hospitalization rates were similar between patients with and without ADT.</p>","PeriodicalId":23366,"journal":{"name":"Turkish journal of urology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/f6/tju-47-6-495.PMC9612749.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish journal of urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/tud.2021.21278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 6

Abstract

Objective: The protective effect of androgen deprivation therapy (ADT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel hypothesis. ADT may protect patients with prostate cancer through the inhibition of androgen receptor-dependent transmembrane serine protease type 2. We analyzed the role of ADT on SARS-CoV-2 infection risk and disease severity.

Material and methods: Between August 2020 and June 2021, patients with prostate cancer were included in our study. Patients were divided into two groups as men receiving ADT or not. Patients' characteristics such as prostate cancer grade and stage, comorbidities, SARS-CoV-2 infection status, and infection severity were assessed. SARS-CoV-2-infected close relatives and patients' compliance with the precautions against SARSCoV- 2 were also analyzed.

Results: A total of 365 patients, 138 (37.8%) with ADT and 227 (62.2%) without ADT, were included in our analysis. Patients with ADT were older (71.8 vs 66.9 years, P ¼ .001) and had a higher rate of chronic obstructive pulmonary disease (11.6% vs 5.7%, P ¼ .044). Patients receiving ADT were more often locally advanced and metastatic (80.4% vs 32.6%, P ¼ .001). SARS-CoV-2 infection rates were statistically similar between patients who received and did not receive ADT (9.4% vs 13.2%, P ¼ .275, respectively). There was no significant difference between two groups in terms of hospitalization rates (2.9% vs 0.9%, P ¼ .205). In multivariate analysis, the presence of SARS-CoV-2-infected close relatives and precautions score were only independent predictors for both risk of SARS-CoV-2 infection and infection severity.

Conclusion: We could not find any effect of ADT on risk and severity of SARS-CoV-2 infection. SARSCoV- 2 infection and hospitalization rates were similar between patients with and without ADT.

Abstract Image

雄激素剥夺治疗对SARS-CoV-2感染率和病情严重程度的临床影响
目的:雄激素剥夺治疗(ADT)对严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的保护作用是一个新的假设。ADT可能通过抑制雄激素受体依赖性跨膜丝氨酸蛋白酶2型来保护前列腺癌患者。我们分析了ADT在SARS-CoV-2感染风险和疾病严重程度中的作用。材料和方法:2020年8月至2021年6月期间,前列腺癌患者纳入我们的研究。患者分为男性和未接受ADT治疗两组。评估患者的特征,如前列腺癌分级和分期、合并症、SARS-CoV-2感染状况、感染严重程度等。分析了sars - cov -2感染的近亲属和患者对sars - cov -2预防措施的依从性。结果:共纳入365例患者,其中ADT患者138例(37.8%),非ADT患者227例(62.2%)。ADT患者年龄较大(71.8岁vs 66.9岁,P < 0.001),慢性阻塞性肺疾病发生率较高(11.6% vs 5.7%, P < 0.044)。接受ADT治疗的患者多为局部晚期和转移性患者(80.4% vs 32.6%, P < 0.001)。接受ADT治疗和未接受ADT治疗的患者的SARS-CoV-2感染率在统计学上相似(分别为9.4%和13.2%,P = 0.275)。两组住院率差异无统计学意义(2.9% vs 0.9%, P < 0.05)。在多因素分析中,近亲属感染SARS-CoV-2和预防措施评分仅是SARS-CoV-2感染风险和感染严重程度的独立预测因子。结论:未发现ADT对SARS-CoV-2感染风险和严重程度有影响。ADT患者和非ADT患者的SARSCoV- 2感染和住院率相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Turkish journal of urology
Turkish journal of urology Medicine-Urology
CiteScore
2.10
自引率
0.00%
发文量
53
期刊介绍: The aim of the Turkish Journal of Urology is to contribute to the literature by publishing scientifically high-quality research articles as well as reviews, editorials, letters to the editor and case reports. The journal’s target audience includes, urology specialists, medical specialty fellows and other specialists and practitioners who are interested in the field of urology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信